Saruparib for hormone-sensitive prostate cancer after docetaxel or Lu-PSMA
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new drug called saruparib combined with a standard hormone therapy for men with metastatic hormone-sensitive prostate cancer who have already been treated with docetaxel or Lu-PSMA therapy and whose PSA level is at least 0.2. The goal is to see if the combination can keep cancer from progressing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with prostate cancer that has spread and is still hormone-sensitive.
- You have already received treatment with docetaxel or Lu-PSMA within the past 6 months, and it did not cause your cancer to progress.
- Your most recent PSA test (within 14 days before starting the trial) was 0.2 ng/mL or higher.
- You are still getting hormone therapy (ADT) or have had your testicles removed surgically, and your testosterone level is very low.
- You are willing to provide a tumor tissue sample and a blood sample for genetic testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding apalutamide to standard hormone therapy (ADT) improves outcomes for men with metastatic hormone-sensitive prostate cancer. Some people may also receive local treatments (like surgery or radiotherapy) to control the prostate and nearby areas.
This study tests combining targeted radiation therapy (guided by special imaging) with a hormone-blocking medication called darolutamide in men with prostate cancer that has spread to other parts of the body. The goal is to see if this combination works better than standard treatment alone.
This Phase 3 trial tests a prostate cancer treatment plan chosen using your tumor’s biomarker results. It aims to improve outcomes for men with metastatic prostate cancer starting first systemic treatment.
This trial is testing if removing the prostate with surgery, after starting hormone therapy, helps men with advanced prostate cancer that has spread to many parts of the body. It aims to see if this approach improves outcomes compared to hormone therapy alone.
This trial tests a new drug, tulmimetostat, combined with standard hormone therapies like darolutamide or abiraterone for men with metastatic prostate cancer that still responds to hormone treatment. The goal is to see if the combination works better than standard therapy alone.
This trial tests whether adding a new drug (saruparib) to standard radiation and hormone therapy can help prevent prostate cancer from spreading to other parts of the body. It is for men with high-risk prostate cancer that has a BRCA gene mutation.
Hear when a new Metastatic Hormone-sensitive Prostate Cancer (mHSPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.